Company intelligence / Profile preview
Xiuzheng Pharmaceutical Group
Tonghua/Liuhe County, Jilin, Chinagojilin.gov.cn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Xiuzheng has commercialized products including herbal medicines and small molecules. Its pipeline includes a biosimilar of rasburicase in Phase 2 for hyperuricemia and an approved product "KangAi" for lung cancer. The company also develops traditional Chinese medicines and modern pharmaceuticals with a focus on metabolic disorders such as hyperuricemia/gout.
- Therapeutic areas
- Metabolic DisordersRheumatologyOncology
- Modalities
- Small moleculeBiosimilarHerbal medicineEnzyme
- Industry
- Pharma
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Xiuzheng Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiuzheng Pharmaceutical Group.